ACRO Biomedical Co

ACRO Biomedical Co Current Assets

The Current Assets of ACRO Biomedical Co (6748.TWO) as of Nov 12, 2026 is 12.70 M TWD. In the previous year, Current Assets was 529.87 M TWD — a change of -97.60% (lower).

Current Assets

12.70 MTWD

YoY

-97.60%

Last updated:

Current Assets of ACRO Biomedical Co is 2025 12.70 M TWD. Current Assets of ACRO Biomedical Co was 2024 529.87 M TWD. It decreases by -97.60% lower compared to the previous year.

The ACRO Biomedical Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
129.09 M TWD
Jan 1, 2019
91.13 M TWD
Jan 1, 2020
152.39 M TWD
Jan 1, 2021
102.17 M TWD
Jan 1, 2022
350.84 M TWD
Jan 1, 2023
607.81 M TWD
Jan 1, 2024
529.87 M TWD
Jan 1, 2025
12.70 M TWD
The ACRO Biomedical Co Current Assets history
YEARCurrent AssetsYoY
12.70 MTWD-97.60%
529.87 MTWD-12.82%
607.81 MTWD+73.25%
350.84 MTWD+243.38%
102.17 MTWD-32.95%
152.39 MTWD+67.23%
91.13 MTWD-29.41%
129.09 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co., Ltd. generates revenue through the development and production of biomaterial medical devices, primarily focusing on collagen scaffolds for tissue engineering and regenerative medicine. The company offers products such as ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray, and ABCcolla External Aesthetic Restoration Prosthesis, all derived from pig skin and pig bone. These products are sold to healthcare providers and medical institutions involved in tissue engineering and regenerative medicine procedures. The firm also engages in international trade and technical services related to its products, expanding its market reach beyond local healthcare sectors. The company's revenue streams are driven by the sale of its specialized collagen-based medical devices, which are designed for applications in tissue repair and aesthetic restoration. ABCcolla Collagen Bone Graft targets bone regeneration, while ABCcolla Collagen Matrix and its variants support soft tissue engineering. ABCcolla Scar Spray addresses scar management, and the External Aesthetic Restoration Prosthesis serves cosmetic and reconstructive needs. These products cater to medical professionals seeking advanced solutions in regenerative medicine. ACRO Biomedical's business model relies on direct sales to healthcare institutions and international trade channels. The firm's focus on pig-derived collagen products positions it as a supplier for tissue engineering applications, with a strong emphasis on regenerative medicine. Technical services complement product sales, enhancing customer retention and recurring revenue opportunities. The company's product portfolio is tailored to meet the specific demands of medical professionals in tissue repair and aesthetic restoration markets. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

Current Assets of ACRO Biomedical Co is 12.70 M TWD in 2025.

Current Assets of ACRO Biomedical Co changed from 529.87 M TWD to 12.70 M TWD, representing a -97.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's ACRO Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co